10x Genomics sued Element Biosciences, alleging that Element’s Aviti24 multiomic spatial platform infringes multiple 10x spatial technology patents licensed from Harvard University. The complaint was filed in U.S. District Court for the District of Delaware and seeks damages, attorneys’ fees, and a permanent injunction. 10x cited specific patent numbers covering analyte detection and sequencing methods, while Element said it strongly disagrees and believes the allegations lack merit. Element argued the lawsuit reflects a broader pattern of using patent portfolios to limit innovation and competition across the spatial biology market. Both companies are pushing spatial workflows beyond nucleic acids, with Aviti24 positioned to capture RNA, protein, morphology, spatial context, and dynamic response—raising the stakes for platform-level IP protections in a rapidly consolidating tool market.